Ideaya Biosciences Inc. is trading 5.4% up at $30.55 today following the announcement of enrolling the first patient in its Phase 1 clinical trial for IDE892 in combination with IDE397. - The trial focuses on MTAP-deleted solid tumors, including non-small cell lung cancer and pancreatic cancer, and preclinical studies showed promising anti-tumor activity. - The company also entered a clinical collaboration with Roche to evaluate IDE892, adding further momentum to the program.